Get started

Relmada Therapeutics, Inc. (United States)

Homepage: relmada.com
Alternate names: Relmada Therapeutics, Relmada Therapeutics, Inc.
ROR: 024ryxb59
OpenAlex ID: I4405267312
N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects
2019 · Manoela V. Fogaça, Kenichi Fukumoto, et al. · Neuropsychopharmacology · 82
PDF
Fabrication of topical metered dose film forming sprays for pain management
2017 · Sneha Ranade, Amrita Bajaj, et al. · European Journal of Pharmaceutical Sciences · 71
Characterization of the Safety and Pharmacokinetic Profile of d-Methadone, a Novel N-Methyl-d-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies
2019 · Galina Bernstein, Kelly Davis, et al. · Journal of Clinical Psychopharmacology · 36
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
2023 · Maurizio Fava, Stephen M. Stahl, et al. · European Archives of Psychiatry and Clinical Neuroscience · 32
PDF
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
2022 · Ezio Bettini, Stephen M. Stahl, et al. · Pharmaceuticals · 31
PDF
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study
2021 · Sara De Martin, Daniela Gabbia, et al. · Frontiers in Pharmacology · 28
PDF
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
2022 · Stephen M. Stahl, Sara De Martin, et al. · International Journal of Molecular Sciences · 24
PDF
The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users
2023 · Megan J. Shram, Jack E. Henningfield, et al. · Translational Psychiatry · 23
PDF
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
2024 · Maurizio Fava, Stephen M. Stahl, et al. · The Journal of Clinical Psychiatry · 17
PDF
REL-1017 (esmethadone; d-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats
2022 · Jack Henningfield, David Gauvin, et al. · Scientific Reports · 15
PDF
N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity
2024 · Stefano Comai, Sara De Martin, et al. · Pharmaceuticals · 13
The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin
2022 · Ezio Bettini, Sara De Martin, et al. · Pharmaceuticals · 13
PDF
Pricing for Multi Indication Medicines: a Discussion With Italian Experts
2022 · L. Pani, A. Cicchetti, et al. · 12
PDF
REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats
2022 · Francesco Bifari, Marco Pappagallo, et al. · Frontiers in Pharmacology · 11
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study
2025 · Maurizio Fava, Luca Pani, et al. · The Journal of Clinical Psychiatry · 9
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment
2024 · Nicola Ferri, Sara De Martin, et al. · Drugs in R&D · 6
Design of solid lipid nanoparticles of the NSAID dexflurbiprofen for topical delivery
2013 · D. Jain, A. Bajaj, et al. · Journal of Pain · 6
Letter to the Editor regarding ‘Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone’
2024 · Marco Pappagallo, Thomas R. Kosten, et al. · Molecular Psychiatry · 5
PDF
Sex-dependent effects of the uncompetitive N-methyl-D-aspartate receptor antagonist REL-1017 in G93A-SOD1 amyotrophic lateral sclerosis mice
2024 · Martina Colognesi, Atea Shkodra, et al. · Frontiers in Neurology · 5
Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder
2023 · Clotilde Guidetti, Giulia Serra, et al. · The Primary Care Companion For CNS Disorders · 5
PDF
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
2023 · Nicola Ferri, Sara De Martin, et al. · Drugs in R&D · 3
PDF
A Phase 2a Double-Blind Randomized Trial of REL-1017 (Esmethadone) in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire
2022 · Clotilde Guidetti, Maurizio Fava, et al. · CNS Spectrums · 3
PDF
Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“
2022 · Marco Pappagallo, Charles E. Inturrisi, et al. · CNS Drugs · 3
PDF
Esmethadone (REL-1017) Restores NMDA Receptor 1 Subunit Expression in an In Vitro Model of Glutamatergic Excitotoxicity
2021 · Sara De Martin, Martina Colognesi, et al. · Biological Psychiatry · 3
There is no better time than the present: nanotechnology as a disruptive innovation for drug development
2015 · Charles Oo, Jui-Chen Tsai, et al. · Drug Discovery Today · 3
Works count: 49
Citation count: 1,678
Year
Topic
Type